GCORE
6.3.2024 09:06:31 CET | Business Wire | Press release
Gcore, the global edge AI, cloud, network, and security solutions provider, today announced the acquisition of StackPath’s web application and API protection (WAAP) solution. A highly regarded security product for protecting applications, the new acquisition will provide Gcore customers with an enhanced, enterprise-grade security solution, incorporating web application firewall (WAF), API security, bot protection, and Layer-7 DDoS mitigation at the edge.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240306076612/en/
Gcore is the global edge AI, cloud, network, and security solutions provider. (Graphic: Gcore)
The acquisition marks a pivotal advancement in Gcore’s mission to deliver comprehensive, edge security services to its customers worldwide. The WAAP will be integrated into Gcore’s security product lineup by Q3 2024.
StackPath WAAP was recognised as a cloud WAF leader by independent security solutions assessor, SecureIQLab in a report comparing the security and operational efficiency of multiple cloud WAF solutions.
Andre Reitenbach, CEO at Gcore, comments: “The acquisition of StackPath WAAP marks a significant milestone in our strategic roadmap, underscoring our commitment to continuous innovation of our solutions and edge infrastructure. With its outstanding reputation for quality, StackPath WAAP stands as a premier solution in the market. Its integration will further strengthen our customers’ application and API security and provide them with enhanced defences against application-layer DDoS attacks at the edge”.
Gcore’s extensive edge network spans over 160 points of presence, delivering fast, reliable, and secure digital experiences worldwide. By leveraging its edge network, Gcore brings protection closer to the end user. This approach reduces latency, scales seamlessly against large-scale DDoS attacks, protects against common vulnerabilities, safeguards critical API endpoints, and leverages real-time threat intelligence. A key advantage of StackPath WAAP is its ability to leverage machine learning to detect and mitigate malicious behaviour. As Gcore incorporates the product into its portfolio, it will enhance its capabilities with AI-driven WAF, enabling advanced identification of HTTP patterns to provide enhanced protection and improve mitigation for zero-day attacks.
Gcore will maintain the rapid setup and out-of-the-box features that have made StackPath WAAP easily configurable, and add capabilities including customisation, advanced threat identification, and real-time analytics. Integration is scheduled by Q3 2024, with an early-access version available for customer evaluation in the meantime. Flexible pricing plans will meet the needs of customers based on usage.
“We’re passionate about security in the cloud and proud of the WAAP we built at StackPath,” said Kip Turco, Chief Executive Officer for StackPath. “When we decided to focus even more specifically on our latency-sensitive, highly distributed edge-computing platform, we knew Gcore would be the perfect home for the continuing innovation of this next-gen WAAP. We look forward to partnering with Gcore even more in the ongoing evolution of cloud, edge, and the security solutions the industry needs.”
About Gcore
Gcore is a global edge AI, cloud, network, and security solutions provider. Headquartered in Luxembourg, Gcore manages its own IT infrastructure across six continents, with leading network performance in Europe, Africa, and LATAM.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240306076612/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex to Acquire Crinetics Pharmaceuticals6.7.2026 22:04:00 CEST | Press release
- Crinetics adds potential best-in-class commercialized and Phase 3 endocrinology assets with ~$5 billion peak sales opportunity to Vertex’s portfolio - - PALSONIFY®, Crinetics’ recently launched, first and only, once-daily oral therapy for adults with acromegaly has demonstrated strong and growing early uptake - - Atumelnant, a once-daily oral adrenocorticotropic hormone (ACTH) receptor antagonist in Phase 3 development for congenital adrenal hyperplasia (CAH), has shown unique and transformative potential to both normalize androgen levels and enable management of patients with physiologic levels of glucocorticoids, the true goal of CAH management; atumelnant has also demonstrated therapeutic potential in patients with Cushing’s syndrome - - Acquisition adds to Vertex’s innovation pipeline, accelerates Vertex’s revenue growth and enhances long-term earnings profile - - Vertex to host investor call today, July 6 at 4:30 p.m. ET - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and C
Ciauru Wins the Second Edition of the Reply AI Music Contest, the International Competition Dedicated to Experimentation Across AI, Music and Live Performance6.7.2026 20:30:00 CEST | Press release
The winner was announced on the Kappa FuturFestival stage, following the performances of the five finalists selected by the international jury.German duo PARAFRAME & Avis Vox received the special Reply AI Studios Grand Prix award. The second edition of the Reply AI Music Contest, the international competition created by Reply to explore new forms of expression combining artificial intelligence, music and live performance, concluded with the announcement of the winner on the Nova Stage powered by Reply during Kappa FuturFestival. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706007611/en/ The second edition of the Reply AI Music Contest, the international competition created by Reply to explore new forms of expression combining artificial intelligence, music and live performance, concluded with the announcement of the winner on the Nova Stage powered by Reply during Kappa FuturFestival First place went to Ciauru, the stag
Rimini Street to Report Second Quarter 2026 Financial Results on July 30, 20266.7.2026 15:00:00 CEST | Press release
Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced it will report earnings after market close on July 30, 2026. The company will host a conference call and webcast on that date to discuss the second quarter 2026 results and the second half 2026 outlook at 5:00 p.m. Eastern / 2:00 p.m. Pacific time. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706560476/en/ Rimini Street to Report Second Quarter 2026 Financial Results on July 30, 2026 A live webcast of the event will be available on Rimini Street’s Investor Relations site via the Rimini Street IR events link and directly via the webcast link. Dial-in participants can access the conference by dialing 1-800-836-8184. A replay of the webcast will be available for one year following the event. About Rimini Street, Inc. Rimini Street, Inc. (Nasda
Orion and Shilpa Medicare Expand Partnership to Develop and Supply Nivolumab Biosimilar for Europe6.7.2026 15:00:00 CEST | Press release
Shilpa Medicare Limited announced that its wholly owned subsidiary, Shilpa Biologicals Private Limited, has entered into a co-development and supply agreement with Orion Corporation for intravenous (IV) nivolumab biosimilar referencing one of the world’s most widely used cancer immunotherapies to widen patient access across Europe. Nivolumab helped usher in the era of immuno-oncology, transforming the outlook for patients with cancers such as melanoma and lung cancer. As the originator approaches loss of exclusivity in Europe, this partnership aims to put a high-quality, EU-GMP-manufactured nivolumab biosimilar within reach of more patients, reducing healthcare burden. In 2025, Nivolumab recorded sales of approximately USD4.1 billion (Source: IQVIA/IMS) Europe — underscoring the scale of the opportunity. Under the agreement, Orion will hold the exclusive rights to register, market, distribute and sell the nivolumab biosimilar across Europe. Shilpa Biologicals will lead product developm
No-Loss Trading Platform UpsideOnly Surpasses 100,000 Users Within Weeks of Launch6.7.2026 14:48:00 CEST | Press release
Rapid growth shows strong demand for a new trading model where users can make market predictions without risking their own capital Perpetuals.com Ltd (Nasdaq: PDC), today announced that UpsideOnly, its risk-free trading and market prediction platform, has seen a surge in new user sign-ups, surpassing the important milestone of 100,000 traders within weeks of its launch on May 19. UpsideOnly lets users make predictions about where global equity, commodity, forex, and crypto markets are heading without ever placing a real trade themselves. Perpetuals uses its own capital to trade on the strongest signals identified by its proprietary AI. If those trades win, Perpetuals shares the profits with the users who helped generate the signal. If the trade doesn’t make money, users lose nothing. Reaching 100,000 users so quickly after launching is a reflection of the enormous demand for a platform that flips the traditional retail trading model on its head, with early platform data showing strong
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
